NCT04444856

Clinical Outcomes of NovoSeven® Treatment in Severe Postpartum Haemorrhage - a Study at the University Hospital of Bern

Clinical Outcomes of NovoSeven® Treatment in Severe Postpartum Haemorrhage - a Retrospective Single-centre Cohort Study at the University Hospital of Bern

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 225 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: Female
• Age: —
• Healthy volunteers: Not accepted

Summary

This non-interventional study will compare the clinical outcomes in women with an event of severe postpartum haemorrhage treated with NovoSeven® to clinical outcomes in women with an event of severe postpartum haemorrhage not treated with NovoSeven®. The study will be a single centre retrospective cohort study of women with an event of severe postpartum haemorrhage, defined as 1.5 L of blood loss within 24 hours of delivery, in the period of 2005-2016.

Conditions

• Severe Postpartum Haemorrhage

Interventions

Type	Name	Description
DRUG	Eptacog alfa (activated)	The women included in the study population have been treated with NovoSeven® (eptacog alfa (activated)) according to local routine clinical practice at the discretion of the treating physician.
OTHER	Standard of care	The women included in the study population have been treated according to local routine clinical practice at the discretion of the treating physician.

Timeline

• Start date: 2020-06-29
• Primary completion: 2021-01-13
• Completion: 2021-01-13
• First posted: 2020-06-24
• Last updated: 2021-01-29

Locations

1 site across 1 country: Switzerland